Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in its $3.5 billion acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results